MedTrace Logo

HIV Risk Reduction and Drug Abuse Treatment in Iran

NCT00398008 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2020-03-30

No results posted yet for this study

Summary

A randomized, double blind clinical trial comparing buprenorphine and naltrexone maintenance treatment when combined with drug abuse and HIV risk reduction counseling (DC-HIV) for heroin and opium addicts in Iran.

Conditions

  • Opiate Dependence
  • HIV Infections

Interventions

DRUG

Buprenorphine/Subutex

Opioid agonist medication to treat opiate dependence

DRUG

Naltrexone

Opioid antagonist medication to treat opiate dependence

BEHAVIORAL

Drug counseling

DC-HIV: Drug Counseling that provides education about HIV, drug abuse and dependence; encourages medication adherence; uses motivational enhancement techniques; encourages life style changes; and teaches cognitive and behavioral coping skills to prevent relapse

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • Yale University

    lead OTHER

Principal Investigators

  • Richard S. Schottenfeld, M.D. · Yale University

  • Azarakhsh Mokri, M.D. · Rouzbeh Hospital, Tehran, Iran

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-10-31
Primary Completion
2006-12-31
Completion
2008-12-31

Countries

  • United States
  • Iran

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00398008 on ClinicalTrials.gov